SWM
BCRX icon

SeaCrest Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

SeaCrest Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$4K – 2143
2018
Q4 		$4K Buy
+500
New +$3.89K ﹤0.01% 1740

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

SeaCrest Wealth Management's BCRX Position: Q1 2019 in Review

SeaCrest Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2019, closing a stake of 500 shares — an estimated $4K sold.

SeaCrest Wealth Management first reported a position in BCRX in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 133 funds tracked by Wall St. Rank hold BCRX as of Q1 2019.

  • SeaCrest Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 500 BioCryst Pharmaceuticals shares in Q1 2019, an estimated $4K.
  • SeaCrest Wealth Management first reported a position in BioCryst Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • SeaCrest Wealth Management's BioCryst Pharmaceuticals position peaked at $4K in Q4 2018.
  • 133 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2019.

Based on SeaCrest Wealth Management's 13F filing for Q1 2019, filed 10 May 2019.